Coming Soon

Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of this study is to test the effectiveness and safety of the combination of an investigational vaccine, PDS0101, and the standard of care, compared to the standard of care treatment alone.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck)

IRB Number

23-2878

ClinicalTrials.gov

NCT06790966

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.

Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/​Metastatic Head and Neck Squamous Cell Carcinoma